Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Archive ouverte

Chari, Ajai | Samur, Mehmet Kemal | Martinez-Lopez, Joaquin | Cook, Gordon | Biran, Noa | Yong, Kwee | Hungria, Vania | Engelhardt, Monika | Gay, Francesca | García Feria, Ana | Oliva, Stefania | Oostvogels, Rimke | Gozzetti, Alessandro | Rosenbaum, Cara | Kumar, Shaji | Stadtmauer, Edward | Einsele, Hermann | Beksac, Meral | Weisel, Katja | Anderson, Kenneth | Mateos, María-Victoria | Moreau, Philippe | San-Miguel, Jesus | Munshi, Nikhil | Avet-Loiseau, Hervé

Edité par CCSD ; American Society of Hematology -

International audience. Abstract The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19–infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

Consulter en ligne

Suggestions

Du même auteur

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. Abstract High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect ...

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviv...

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Archive ouverte | Samur, Mehmet Kemal | CCSD

International audience. PURPOSE Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequ...

Chargement des enrichissements...